| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/12/2009 | US20090069383 Thrombin Receptor Antagonists |
| 03/12/2009 | US20090069380 Deuterium-enriched aroxifene |
| 03/12/2009 | US20090069379 Deuterium-enriched lenalidomide |
| 03/12/2009 | US20090069377 Deuterium-enriched enzastaurin |
| 03/12/2009 | US20090069376 Substituted N [N-(sulphonylphenyl)sulfonyl-prolyl]-phenylalanine derivatives are antagonists of the very late antigen-4 integrin; ulcerative colitis, Crohn's disease, asthma, multiple sclerosis, rheumatoid arthritis |
| 03/12/2009 | US20090069371 Isoquinoline compounds |
| 03/12/2009 | US20090069367 Methods for treatment of cancer |
| 03/12/2009 | US20090069362 Novel Spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| 03/12/2009 | US20090069360 Organic Compounds |
| 03/12/2009 | US20090069359 A formulation for treatment of alopecia contains minoxidil, urea, hydrocortisone and a skin desquamation agent comprising tretinoin |
| 03/12/2009 | US20090069354 Deuterium-enriched gemcitabine |
| 03/12/2009 | US20090069350 Pharmaceutical compositions and use thereof |
| 03/12/2009 | US20090069349 Deuterium-enriched pemetrexed |
| 03/12/2009 | US20090069341 Inhibitors of hsp90 |
| 03/12/2009 | US20090069338 Method for predicting skin sensitizing activity of compounds |
| 03/12/2009 | US20090069336 Pyrimidothiophene compounds |
| 03/12/2009 | US20090069331 Guanidine derivatives as inhibitors of ddah |
| 03/12/2009 | US20090069325 Piperidine Derivatives Useful as Modulators of Chemokine Receptor Activity |
| 03/12/2009 | US20090069324 Chemical inhibitors of bfl-1 and related methods |
| 03/12/2009 | US20090069319 Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| 03/12/2009 | US20090069316 Novel quinoline derivatives |
| 03/12/2009 | US20090069314 Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods |
| 03/12/2009 | US20090069307 Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions |
| 03/12/2009 | US20090069303 Phthalazinone derivatives |
| 03/12/2009 | US20090069301 Acridine and Quinoline Derivatives as Sirtuin Modulators |
| 03/12/2009 | US20090069297 protein kinase inhibnitors such as N-(4-((7-(methyloxy)-1,5-naphthyridin-4-yl)oxy)phenyl)-4-phenyl-1-phthalazinamine, for influencing the process of cell cycle and cell proliferation to treat cancer; anticarcinogenic agents |
| 03/12/2009 | US20090069294 Organic Compounds |
| 03/12/2009 | US20090069288 Novel therapeutic compounds |
| 03/12/2009 | US20090069281 Ansamycin formulations and methods of use thereof |
| 03/12/2009 | US20090069280 17-amino analogs of geldanamycin, used for treating and modulating disorders associated with hyperproliferation, such as cancer; antiproliferative and anticarcinogenic agents |
| 03/12/2009 | US20090069225 Somatostatin analogues |
| 03/12/2009 | US20090069221 Somatostatin Analogue Formulations |
| 03/12/2009 | US20090068720 Useful polypeptides |
| 03/12/2009 | US20090068695 Detecting activity of a Silent information regulator 2 by combining the composition with adenosine 5'-diphosphate and an acetylated Sir2 peptide substrate to deacetylate the peptide, and identifying 2'/3'-O-acetyl-ADP-ribose in the mixture to determine the presence of Sir2 activity |
| 03/12/2009 | US20090068295 Composition for treating cancer and method of using the same |
| 03/12/2009 | US20090068286 Method of treating cancer by administration of 5-substituted nucleosides |
| 03/12/2009 | US20090068257 Betulonic and betulinic acid derivatives |
| 03/12/2009 | US20090068255 Use of matrix metalloproteinase inhibitors in skin care |
| 03/12/2009 | US20090068234 Methods and compositions for the treatment and prevention of cancer |
| 03/12/2009 | US20090068224 Method to identify polypeptide toll-like receptor (tlr) ligands |
| 03/12/2009 | US20090068209 Cytotoxic Lymphocyte |
| 03/12/2009 | US20090068202 Humanized Anti-CD79B Antibodies and Immunoconjugates and Methods of Use |
| 03/12/2009 | US20090068200 Method for Prongf Assay for in Vitro Diagnosis of Cancer in Particular Breast, Thyroid or Lung Cancer, and Therapeutic Use of Prongf |
| 03/12/2009 | US20090068199 Methods for Treating and Detecting Beta-Cell Disease |
| 03/12/2009 | US20090068198 Antibody and Uses Thereof |
| 03/12/2009 | US20090068195 Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
| 03/12/2009 | US20090068192 The antibodies are immunomodulators of diseases such as cancer, autoimmune, inflammatory and infectious diseases |
| 03/12/2009 | US20090068190 Anti-proliferative combinations |
| 03/12/2009 | US20090068188 C-C chemokine receptor 3 proteins |
| 03/12/2009 | US20090068186 MAP3Ks as modifiers of the p53 pathway and methods of use |
| 03/12/2009 | US20090068183 Method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same |
| 03/12/2009 | US20090068182 Cytotoxicity mediation of cells evidencing surface expression of CD9 |
| 03/12/2009 | US20090068178 Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| 03/12/2009 | US20090068171 Protein markers for the detection of thyroid cancer metastasis |
| 03/12/2009 | US20090068166 Method and composition for protection against radiation |
| 03/12/2009 | US20090068164 Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences |
| 03/12/2009 | US20090068151 Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| 03/12/2009 | US20090068146 Diaryl ureas and combinations |
| 03/12/2009 | US20090068145 Methods and Compositions Relating to Islet Cell Neogenesis |
| 03/12/2009 | US20090068144 Tetrahydro-isoquinolin-1-ones for the treatment of cancer |
| 03/12/2009 | US20090068141 Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer |
| 03/12/2009 | US20090068139 LOOP PEPTIDE AND TGF alpha FOR STIMULATING STEM CELL PROLIFERATION AND MIGRATION |
| 03/12/2009 | US20090068108 Biospecific contrast agents |
| 03/12/2009 | US20090068104 Substantially Homogeneous Bio-Affecting Material Having a Pre-Determined Ratio of Bioaffecting Component to Cell Targeting Component, the Method for Making Such a Material and the Method of its use |
| 03/12/2009 | US20090068099 Cancerous disease modifying antibodies |
| 03/12/2009 | US20090068098 Antibodies and related molecules that bind to 58p1d12 proteins |
| 03/12/2009 | US20090068096 Sequence of stro-1 antibody variable region |
| 03/12/2009 | US20090068095 Carbonic anhydrase ix (g250) anitbodies and methods of use thereof |
| 03/12/2009 | US20090068094 Inhibitors of endo-exonuclease activity for treating cancer |
| 03/12/2009 | DE102007042107A1 Pharmaceutical composition, e.g. for tumor therapy, comprises an iron-binding agent coupled to an active ingredient through a peptide linker comprising a protease recognition sequence |
| 03/12/2009 | CA2698771A1 Microrna signatures in human ovarian cancer |
| 03/12/2009 | CA2698753A1 Pyrazolo-pyridines as tyrosine kinase inhibitors |
| 03/12/2009 | CA2698747A1 Estrogenic extracts of scuttelaria barbata d. don of the labiatae family and uses thereof |
| 03/12/2009 | CA2698671A1 Use of adenosine aspartate for the preparation of pharmaceutical products for the treatment of liver cancer |
| 03/12/2009 | CA2698665A1 Pharmaceutical composition for inhibiting amyloid-beta protein accumulation |
| 03/12/2009 | CA2698396A1 Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof |
| 03/12/2009 | CA2698173A1 Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof |
| 03/12/2009 | CA2698062A1 Thiadiazinone derivatives |
| 03/12/2009 | CA2697934A1 1,3-dihydroisoindole derivatives |
| 03/12/2009 | CA2697737A1 Method for promoting expression of p53, and p53 expression promoter for use in the method |
| 03/12/2009 | CA2697482A1 Combination therapy with type i and type ii anti-cd20 antibodies |
| 03/12/2009 | CA2696824A1 Compounds and compositions as kinase inhibitors |
| 03/12/2009 | CA2691115A1 Stabilized picoplatin dosage form |
| 03/12/2009 | CA2684037A1 Compounds with anti-cancer activity |
| 03/11/2009 | EP2034030A2 Novel compositions and methods for cancer |
| 03/11/2009 | EP2034017A1 Gene involved in immortalization of human cancer cell and use thereof |
| 03/11/2009 | EP2034009A2 Compositions and methods for restoring immune responsiveness in patients with immunological defects basing on cd3/cd28 costimulation |
| 03/11/2009 | EP2033972A1 Screening method for candidate drugs |
| 03/11/2009 | EP2033965A2 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents |
| 03/11/2009 | EP2033963A1 Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives |
| 03/11/2009 | EP2033962A1 Tetracyclic indolopyridines as EG5 inhibitors |
| 03/11/2009 | EP2033959A1 Tetrahydropyranoquinoline derivatives |
| 03/11/2009 | EP2033956A1 A new class of histone deacetylase inhibitors |
| 03/11/2009 | EP2033657A1 Intraoperative trifunctional antibody application for prophylatic intraperitonal tumour cell dissemination |
| 03/11/2009 | EP2033648A2 Sustained release drug delivery system containing codrugs |
| 03/11/2009 | EP2033640A2 Beta-lapachone for the treatment of lung cancer |
| 03/11/2009 | EP2033639A2 Beta-lapachone for the treatment of colon cancer |
| 03/11/2009 | EP2033638A2 Beta-lapachone for the treatment of pancreatic cancer |
| 03/11/2009 | EP2033637A1 Therapeutic or prophylactic agent for leukemia |
| 03/11/2009 | EP2033512A1 Model animal of dendritic cell immunoreceptor gene knockout disease |